Materials & Resources » Chemicals | Hubei Biocause Pharmaceutical Co. Ltd.

Hubei Biocause Pharmaceutical Co. Ltd. A | Cash Flow

Fiscal year is January-December. All values CNY Millions.
2013
2014
2015
2016
2017
Other Funds
33
13
14
9,700
4,773
Funds from Operations
45
45
3
9,529
1,950
1,619
Changes in Working Capital
145
98
54
6,551
5,203
20,738
Net Operating Cash Flow
100
143
57
2,978
7,153
22,357
Capital Expenditures
144
186
41
3,678
779
Sale of Fixed Assets & Businesses
19
103
10
17,234
1
Purchase/Sale of Investments
-
225
162
16,197
16,771
Net Investing Cash Flow
182
148
131
2,734
17,596
Cash Dividends Paid - Total
-
-
-
41
106
Issuance/Reduction of Debt, Net
54
71
71
1,000
6,003
Net Financing Cash Flow
21
58
58
10,626
10,668
Net Change in Cash
61
53
16
10,874
223
Free Cash Flow
44
328
98
700
6,374
Other Sources
89
5
-
-
-
Change in Capital Stock
-
-
-
-
1
Exchange Rate Effect
-
-
-
4
2
Other Uses
147
-
-
92
48

About Hubei Biocause Pharmaceutical Co.

View Profile
Address
No. 132 Yangwan Road
Jingmen Hubei 448000
China
Employees -
Website http://www.biocause.com
Updated 07/08/2019
Hubei Biocause Pharmaceutical Co., Ltd. engages in the research, development, manufacture and sale of chemical products and medicinal raw materials. Its products include homatropine hydrobromide, thiotriazoline, lercanidipine hydrochloride, barnidipine hydrochloride, mitoxantrone hydrochloride, hyoscyamine sulfate, balsalazide sodium, oxaprozin, homatropine methyl bromide, flumazenil, milrinone, granisetron hydrochloride and others. The company was founded on November 18, 1993 and is headquartered in Jingmen, China.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.